Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ch related initiatives, including:

  • Significant management additions to U.S. commercial team: VP Sales; Senior Director, Marketing; and Director, Commercial Operations
  • Market research updates to support launch planning and sales force sizing
  • Continued pursuit of our desired reimbursement scenarios for Qutenza

The Company expects to provide an update and additional details on U.S. commercialization plans once it learns the outcome of the FDA review of Qutenza in PHN.

In late September 2009, the Company completed the transfer of the Qutenza Marketing Authorization (MA) to Astellas, which is now the legal holder of the MA. In accordance with the licensing agreement between NeurogesX and Astellas, the MA transfer supports the E.U. launch of Qutenza for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. As a result of the MA transfer, Astellas is now responsible for ongoing maintenance of the MA, including certain post-marketing commitments for a safety and efficacy study of Qutenza.

In addition to Qutenza launch preparation activities, the Company appointed Bradford S. Goodwin to its Board of Directors as a director and Audit Committee chairman. Mr. Goodwin is currently President and CEO of Keren Pharmaceutical, nonexecutive chairman of Facet Biotech Corp. and a director of Rigel, Inc. He is a healthcare industry veteran that has held various senior executive positions at Novacea, Inc., Collabra Pharma, and Genentech, Inc.

Anthony DiTonno, President and CEO, commented, "The NeurogesX team continues to operate at exceptional levels as our focus remains squarely fixed on the upcoming PDUFA date for the potential U.S. approval of Qutenza in PHN. During the third quarter our commercialization readiness activities for Qutenza took center stage. Turning towards the E.U. launch, our highly collaborative and posit
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Mass. and SYDNEY, Sept. 14, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that CEO Doug Godshall is scheduled ... at 10:30 a.m. ET on Wednesday, September 21, 2011. ...
... Sept. 14, 2011 Tengion, Inc. (NASDAQ: TNGN ... Davis, Vice President Finance and Chief Financial Officer of Tengion, ... on Monday, September 19, 2011, at 1:30 pm EDT. ... accessed under "Calendar of Events" in the Investors section of ...
... 13Researchers at Vanderbilt University have developed a new technique that ... tissue at multiple points simultaneously, a method that could help ... and change shape. UV lasers are a commonly-used ... incisions by vaporizing one point at a time in a ...
Cached Biology Technology:HeartWare to Present at the UBS Global Life Sciences Conference 2Tengion to Present at UBS Global Life Sciences Conference 2
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... Scientists have conclusive evidence that the source of a ... Ocean and called the "bio-duck," is the Antarctic minke ... by submarine personnel in the 1960s who thought it ... recorded at various locations in the Southern Ocean, but ... In February 2013, an international team of researchers deployed ...
(Date:4/23/2014)... accurate group decision increases with the abundance of brains ... a variety of factors as often happens in ... smaller groups actually tend to make more accurate decisions ... certain pieces of information. , The findings present a ... or the "wisdom of crowds," wherein individual observations ...
Breaking Biology News(10 mins):Picky male black widow spiders prefer well-fed virgins 2Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... ARBOR, Mich. Researchers from the University of Michigan ... overexpressed in 90 percent of pancreatic cancers, the most ... Ataxia Telangiectasia Group D Complementing gene, called ATDC, is ... than in cells from a normal pancreas. What,s more, ...
... Germany March 2, 2009 >> Genomatix Software, a ... Next Generation Sequencing (NGS) data, announced today that Boehringer ... Mining Station and a Genomatix Genome Analyzer at its ... the only complete and integrated analysis solution for NGS ...
... of Illinois plant geneticist Stephen Moose has developed a corn ... that would make good silage, Moose said, due to a ... make it a good energy crop. The gene known ... giving corn seedlings a waxy coating that acts like a ...
Cached Biology News:U-M researchers ID gene involved in pancreatic cancer 2Boehringer Ingelheim uses Genomatix' Next Generation Sequencing data analysis systems 2Doubling a gene in corn results in giant biomass 2
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
Request Info...
Request Info...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Biology Products: